Nutra Pharma Announces Publication Of Positive Results Of ReceptoPharm Arthritis Study

Main Category: Arthritis / Rheumatology
Article Date: 19 Feb 2009 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced that its wholly-owned drug discovery subsidiary, ReceptoPharm, in collaboration with Soochow University in China has published strong data from its recent animal studies on the use of RPI-78 (Cobratoxin) as a method for treating arthritis. RPI-78 is ReceptoPharm's lead drug candidate currently being studied for the treatment of pain.

"While we were aware that RPI-78 had analgesic activity, the purpose of this study was to examine the specific anti-inflammatory effects of RPI-78 in an animal model of rheumatoid arthritis," explained Dr. Paul Reid, CEO of ReceptoPharm. "The results demonstrate that RPI-78 acts by modulating the immune system's production of inflammatory cytokines and lessens autoimmune damage to the joint," he added.

The study was published in the February 2009 issue of Acta Pharmacologica Sinica, an international monthly publication and the official journal of the Chinese Pharmacological Society and Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

Recently, ReceptoPharm announced the filing of a patent application with the United States Patent and Trademark Office for the use of RPI-78 as a novel method for treating arthritis in humans.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com
http://www.ReceptoPharm.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). ReceptoPharm's positive results from its study of RPI-78 (Cobratoxin) for the treatment of arthritis should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at http://www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Nutra Pharma Corp.